Tang Yue, Deputy to the National People's Congress and Chairman of Chutian Technology: Promoting the R&D of Biopharmaceutical Equipment to Meet the "Era of Pharmaceutical Industry 4.0

Jul 03, 2020

⊙Reporter Xia Zihang ○ Editor Xu Rui

Just as the National People's Congress deputy, Chu Tian Technology Chairman Tang Yue foresaw a few years ago, where the pharmaceutical industry is fully entering the "pharmaceutical industry 4.0 era." In his view, it is very important to deepen the public health reform of the disease control system, establish a modern disease control management system, and accelerate the development of biopharmaceutical equipment.

Develop pharmaceutical equipment to help prevent and control COVID-19

"The new coronavirus, which has a high infection rate, a long incubation period, and multiple transmission routes, poses a huge challenge to the world's pharmaceutical industry." Tang Yue said.

At this year's two national conferences, Tang Yue put forward "suggestions on accelerating the development of biopharmaceutical equipment and improving local disease prevention and control capabilities." "Biopharmaceuticals are an important part of the national economy and have a closer relationship with people's livelihood. The main popular figure Tang Yue said that at present, the gap between the level of domestic biotechnology and biopharmaceutical core equipment is far from the world's advanced level.

In response to this problem, Tang Yue suggested that the state should introduce supporting policies to encourage the development of biopharmaceutical equipment, focusing on enhancing the emergency production capacity of epidemic prevention and control products; further promoting traditional Chinese medicine, accelerating the research level of Chinese medicine preparation equipment, and promoting Chinese medicine preparation equipment Quickly realize automation, digitalization, and intelligent upgrades; at the same time, encourage school-enterprise cooperation to achieve integrated development of production, education, and research, make full use of talents from universities, research institutes, R&D, technological advantages, and enterprise platforms and market advantages, and actively promote R&D and production, Close cooperation in sales.

The arrival of "the era of pharmaceutical industry 4.0"

A few years ago, Tang Yue said to the Shanghai Securities Journal reporter that in the future, the medical equipment industry will usher in a continuous huge dividend in the world, that is, "pharmaceutical industry 4.0" and the upgrading of pharmaceutical intelligent manufacturing. The direction of development will be obvious after 5 years, and there will be changes in the outline after 10 years. In Tang Yue's view, "Pharmaceutical Industry 4.0" can greatly reduce the hidden dangers of medical safety.

According to reports, pharmaceutical intelligent manufacturing and "Pharmaceutical Industry 4.0" can realize real-time, online, full-range, all-round automatic monitoring of pharmaceutical manufacturing and circulation consumption, and automatically generate data (and cannot be tampered with), automatically read data, Automatically store data to the cloud, zero delays, no dead ends, no blind spots. According to the authorization of the law, regulatory authorities, drug producers, and consumers can consult and retrieve relevant data.

Tang Yue believes that in the future, high-end pharmaceutical equipment, "pharmaceutical industry 4.0" and intelligent manufacturing will be regarded as "rigid demand" for pharmaceutical factories. Based on long-term foresight, Chutian Technology has successfully developed some intelligent pharmaceutical production robots and related production lines using automation and information technology and is transforming into an EPC service provider that builds a "pharmaceutical industry 4.0" smart factory overall solution.

The 2019 annual report shows that Chutian Technology's industrial layout has begun to show its advantages. The traditional advantage of Chutian Technology lies in the liquid pharmaceutical equipment, and its production and sales are at the forefront of the industry; Chutian Huatong, a wholly-owned subsidiary, is a professional research and development of pure steam generator, multi-effect distilled water machine, purified water preparation system, and other products. Manufactured pharmaceutical equipment manufacturing enterprise; Military Pharmaceutical Engineering Design Service of Sichuan Pharmaceutical Design Institute, a wholly-owned subsidiary; Chutian Robot, the holding subsidiary's main products are medical and medical robots; in 2019, Chutian Technology has added an intelligent Chinese medicine machinery product line.

Chutian Technology recently stated on the interactive platform that Sichuan Pharmaceutical Design Institute, a wholly-owned subsidiary of the company, has the design and construction capabilities of the P3 Biosafety Laboratory. During the epidemic prevention and control period, Sichuan Medical Design Institute undertook the design of the high-level biosecurity laboratory (P3) of the Eighth People's Hospital of Guangzhou City, which was highly recognized by hospital experts.

Currently, Chutian Technology is planning a follow-up merger and acquisition of ROMACO. ROMACO is currently the seventh-largest medical equipment company in the world and a senior solid preparation packaging manufacturer. Its products have entered more than 100 countries and regions in the world.